KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Non Operating Income (2017 - 2025)

Historic Non Operating Income for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to -$75.6 million.

  • Amneal Pharmaceuticals' Non Operating Income fell 297.2% to -$75.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$289.2 million, marking a year-over-year increase of 697.37%. This contributed to the annual value of -$304.3 million for FY2024, which is 2440.08% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Non Operating Income of -$75.6 million as of Q3 2025, which was down 297.2% from -$59.7 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Non Operating Income peaked at -$27.5 million during Q4 2021, and registered a low of -$97.7 million during Q4 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' median Non Operating Income value was -$50.4 million (recorded in 2023), while the average stood at -$53.8 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Non Operating Income skyrocketed by 3024.73% in 2021, and later crashed by 12353.1% in 2023.
  • Amneal Pharmaceuticals' Non Operating Income (Quarter) stood at -$27.5 million in 2021, then plummeted by 58.9% to -$43.7 million in 2022, then crashed by 123.53% to -$97.7 million in 2023, then rose by 6.7% to -$91.1 million in 2024, then grew by 17.06% to -$75.6 million in 2025.
  • Its last three reported values are -$75.6 million in Q3 2025, -$59.7 million for Q2 2025, and -$62.9 million during Q1 2025.